论文部分内容阅读
The purpose of this study is to prepare tumor-specific dual-mode nanobubbles as both ultrasound contrast agents (UCAs) and near-infrared fluorescence (NIRF) imaging agents.Recently,some researches about conjugating against-tumor ligands on the surface of nanobubbles as molecule-targeting ultrasound contrast agents for tumor have been reported.However,the complicated procedure has also posed a challenge to nanobubbles' stability and ability of targeting and imaging.Thus, in the present study, we prepared nanobubble-IR-780 by combining NIRF IR-780 iodide with phospholipids-film of nanobubbles that we have constructed and the physical features were detected.Furthermore, the tumor-targeting characteristic of the nanobubble-IR-780 has been observed in different tumor cells in vitro, the tumor-specific ultrasound contrast imaging and NIRF imaging by the nanobubble-IR-780 was verified in vivo.The results showed that the new nanobubble-IR-780 took on uniform nano-size [(442.5±48.6)nm] ,well NIR imaging, ultrasound imaging, stability and safety.Then, the nanobubble-IR-780 can accumulate automatically on different tumor cells i n vitro but not on cardiac muscle cells used as negative control and the targeting rate was considerable(be close to 40%).Importantly, the nanobubble-IR-780 can detect tumor precisely via dual-mode imaging in vivo.In conclusion, the new dual-mode nanobubble-IR-780 has potential advantage of non-invasive tumor-specific detection via contrast enhanced ultrasound and NIRF imaging.